安徽省高值肺癌靶向代表药物可及性分析及实证研究  

Availability analysis and empirical study of representative targeted drugs for high-value lung cancer in Anhui Province

作　　者：吴颖其 张圣雨 王猛 吴菲[1] 朱鹏里 沈爱宗 WU Yingqi;ZHANG Shenyu;WANG Meng;WU Fei;ZHU Pengli;SHEN Aizong(Department of Pharmacy,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Univer-sity of Science and Technology of China,Hefei,Anhui 230001,China)

机构地区：[1]中国科学技术大学附属第一医院(安徽省立医院)药剂科,安徽合肥230001

出　　处：《安徽医药》2022年第4期836-840,共5页Anhui Medical and Pharmaceutical Journal

基　　金：2018年高等学校省级质量工程项目(2018jyxm0749,2018sxzx57)。

摘　　要：目的 分析安徽省高值肺癌靶向代表药物吉非替尼(OBs)、吉非替尼(LPGs)和厄洛替尼(OBs)的药品可及性现状。方法通过文献分析法、专家访谈法和实证研究等途径获取药品价格水平、可获得性和可负担性三方面指标,运用WHO/HAI药物可及性标准化方法分析药品可及性现状。价格水平指标获取2019年同期价格;可获得性指标研究的时间为2019年1月至12月;可负担性实证研究对象为2017—2019年数据。结果 两个进口药品在安徽省的价格水平均为当地可接受价格(MPR<2)。可获得性方面吉非替尼总体可获得性82.20%(180/219)高于厄洛替尼60.73%(133/219),在公立机构三种药品配备率均较高(57.35±6.58)%,但在私立机构(48.28±10.49)%尤其是药店进口药品(34.38±4.42)%配备不足。仅部分地区三种药品的可获得性差异有统计学意义(皖中比合肥,α<0.012 5)。可负担性实证研究中住院病人陷入“灾难性支出”(40.62±17.02)%,经医保报销后病人可负担性转归(13.10±8.72)%,城镇(5.04±5.20)%可负担性好于农村(16.00±9.21)%,并有逐年转归的趋势。结论三种药品在安徽省各个地区的可获得性均较高;高值靶向药物的可及性在逐年增加。Objective To analyze the current status of drug availability of the high-value lung cancer targeted representative drugs gefitinib (OBs),gefitinib (LPGs) and erlotinib (OBs) in Anhui Province.Methods Three indicators of drug price level,availability and affordability were obtained through literature analysis,expert interviews and empirical research,and the current status of drug availability was analyzed using the WHO/HAI standardization method.The price level indicator obtains the price in the same period of 2019.The research time of the availability indicator is from January to December 2019.The empirical research object of affordability is the three-year data from 2017 to 2019.Results The price levels of the two imported drugs in Anhui Province are both acceptable local prices (MPR<2).In terms of availability,the overall availability of gefitinib[82.20%(180/219)]was higher than that of erlotinib[60.73%(133/219)],and the allocation rates of the three drugs in public institutions were all higher (57.35±6.58)%,but in private institutions (48.28±10.49)%,especially imported drugs (34.38±4.42)%were underequipped.Only in some regions was there a statistically significant difference in the availability of the three medicines (Hefei vs.Wanzhong,α<0.012 5).In the empirical study of affordability,inpatients fell into"catastrophic expenditure"(40.62±17.02)%,and after reimbursement by medical insurance,the affordability outcome of patients was (13.10±8.72)%,and the affordability that in urban (5.04±5.20)%was better than rural areas (16.00±9.21)%.There was a tendency to return year by year.Conclusions The availability of the three drugs is relatively high in various regions of Anhui Province.The availability of high-value targeted drugs is increasing year by year.

关 键 词：肺肿瘤 分子靶向治疗 高值靶向药物 可及性 实证研究 

分 类 号：R734.2[医药卫生—肿瘤]